Jab Link to HIV to be Tested
The long-awaited trial that plans to answer whether a contraceptive injection increases a woman’s risk of contracting HIV is set to begin this month.
December 1, 2015 — Times Lives
Why Don’t Women Know About This Lifesaving Drug?
Considering what a tremendous impact this drug has had on the gay community (and the fact that my female friends are among the smartest people I know), I started asking myself, Why aren’t more women talking about PrEP?
December 1, 2015 — Refinery29
5 People Who Changed the Face of HIV
Today marks the 27th annual World AIDS Day — a global celebration and commemoration of the fight to educate and eradicate HIV and AIDS. Here we look at five key celebs whose diagnoses changed the face of HIV and AIDS.
December 1, 2015 — New York Post
UN Plan to Halt HIV Needs More Money, Less Complacency
The world committed to end the AIDS epidemic by 2030 with goals adopted this year by the United Nations. But is that realistic, or even possible?
December 1, 2015 — Chicago Tribune
US Still in Danger of Losing War on AIDS, CDC Director Says
Despite major medical advances and more than 30 years of effort, the United States is still in danger of losing the war on AIDS, according to the country’s top disease-control official.
December 1, 2015 — New York Times
When Can We Expect PrEP 2.0?
Benjamin Ryan ofPOZdiscusses what’s in the PrEP pipeline, looking forward to long-acting injectables and drugs less toxic than Truvada.
December 1, 2015 — POZ
HIV Prophylaxis Could Benefit 1.2 Million: CDC
About 1.2 million people in the US are at “substantial risk” of HIV and could benefit from taking a daily pill to prevent the infection, the CDC said.
November 25, 2015 — MedPage Today
1 In 4 Gay Men Should Take The Pill That Prevents HIV, CDC Says
A report released by the US CDC finds that roughly 1.2 million people would benefit from PrEP based on their reported rates of otherwise unprotected risk behavior. That’s about 60 times higher than current estimates, which suggest about 21,000 people take the drug.
November 24, 2015 — BuzzFeed
Can Charlie Sheen Really Have Doctor-Approved Unprotected Sex?
David Kauffman of theNew York Postwrites how Charlie Sheen’s announcement on being HIV-positive introduced America to the range of treatment options that are already available.
November 17, 2015 — New York Post
This Doctor Invented The HIV Blood Test. Now He Has A Vaccine That May Beat The Virus
In 1984, Dr. Robert Gallo co-discovered HIV as the cause of AIDS, then went on to pioneer the blood test that detects the virus. Now, 31 years later, his team at the University of Maryland School of Medicine’s Institute of Human Virology is beginning human trials this month on a potentially revolutionary HIV vaccine.
October 13, 2015 — HuffPost Science
HIV Vaccine to be Tested on People
After years of research, a promising HIV/AIDS vaccine at the University of Maryland School of Medicine is moving into the critical human testing stage. The institute’s vaccine is just one of about 30 such drugs in some stage of human trials, according to AVAC, an advocacy group devoted to HIV prevention efforts.
October 9, 2015 — Baltimore Sun
Accessibility to Sexual Health Resources Among Diverse Populations
Steph Auteri, writing foraasect, links an NYT article on a highly successful IUD promotion campaign in the US to what it will really take to address women’s sexual and reproductive health needs, including commentary on PrEP from IRMA’s Jim Pickett and AVAC’s Mitchell Warren.
October 6, 2015 — Aasect
WHO on HIV Therapy: Treat Everyone
Everyone with HIV should be offered treatment immediately upon diagnosis, according to new World Health Organization (WHO) guidelines. The recommendation — dropping any eligibility restrictions for antiretroviral therapy — brings WHO advice into line with guidelines in the U.S., and most other Western countries.
October 5, 2015 — MedPage Today
Health Journalists Link Up with Scientists at Science Cafés
The Health Journalists Network in Uganda, dedicated to increasing understanding of health care issues and improving health literacy among Africans, organizes Science Cafés in partnership with AVAC. Science Cafés present a platform for unique public engagement on issues that may be rather isolated from the general public including journalists.
September 30, 2015 — Africa Science Technology & Innovation News
Insurer Says Clients on Daily Pill Have Stayed HIV Free
Demonstrating that take a daily pill to prevent HIV infection can work in the real world, San Francisco’s largest private health insurer announced Wednesday that not one of its 657 clients receiving the drug had become infected over a period of more than two years.
September 2, 2015 — NY Times
HIV Vaccine Trial Starts in Zimbabwe
Zimbabwe will start its first HIV vaccine clinical trial as soon as regulatory approvals are achieved. The trial, named HVTN 107, will enroll 24 Zimbabwean participants (of a planned total 132 participants) to test a vaccine similar to the one that reduced risk of HIV infection by 31 percent in the RV144 trial in Thailand. HVTN 107 will also run in South Africa and Mozambique. An overview of AIDS vaccine research can be foundhere.
August 30, 2015 — Zim Daily
HIV Testing Is Down And STDs Are Up As New York City Closes Free Clinics
New York City, which has one of the country’s highest rates of new HIV infections, has been quietly cutting many of the prevention services needed to fight the epidemic, according to many AIDS advocates.
August 27, 2015 — BuzzFeed
Mitchell Warren on HIV prevention research
Fred Schaich of IFARA speaks with Mitchell Warren, executive director of AVAC, about HIV prevention research presented at IAS 2015.
August 24, 2015 — The Body Pro
Did AIDS Healthcare Foundation Just Change Its Tune on PrEP?
After strongly advocating against PrEP, the AIDS Healthcare Foundation’s new national ad campaign includes eleven principles on how to include PrEP as part of an HIV prevention strategy.
August 19, 2015 — HIVPlusMag
AIDS Healthcare Foundation Cedes Ground in Anti-PrEP Fight
The AIDS Healthcare Foundation, which has long waged a vociferous battle against Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP), has finally begun to offer measured support for the HIV prevention method.
August 18, 2015 — AIDSMEDS
2015 GLAM Awards and Toolkit Promote Lube Access in Latin America
2013 and 2014 Global Lube Access Mobilization (GLAM) grants were awarded to partners in Africa to support their efforts advocating lubricant availability and educating gay men, men who have sex with men and transgender individuals about its proper use.
August 13, 2015 — The Body
Barré-Sinoussi: There is Less Attention for HIV
According to Nobel laureate Françoise Barré-Sinoussi, AIDS research has made immense progress over the last decades, but there’s still a lot to be done. She says less attention is being paid to HIV in wealthy countries.
August 4, 2015 — DW
Right things, right places, right targets — right now
Over the past decade, the US President’s Emergency Plan for AIDS Relief — in partnership with other countries and financing mechanisms — has helped change the trajectory of the AIDS epidemic. Yet, right now, PEPFAR is operating without targets. Read why targets are necessary and how they drive action.
August 3, 2015 — Devex
Here’s What We Actually Know About the Pill that Prevents HIV
The new National HIV/AIDS Strategy (NHAS), now updated for 2015-2020, is focused heavily on prevention and includes a strong endorsement of PrEP as a strategic option. This article inBuzzFeedtakes on six common misconceptions about PrEP and clarifies what the science really has to say about this blue pill.
August 2, 2015 — BuzzFeed
How to Beat HIV
In the past, there was a sense that stopping the HIV/AIDS epidemic would require some radically new biomedical intervention. The growing consensus, however, is that the tools needed to stamp out HIV already exist if they could just be used in the right way.
July 7, 2015 — Nature
New AIDS Vaccine Protects Monkeys
An experimental vaccine protected half of a batch of monkeys against a virus similar to the AIDS virus, scientists reported.
July 2, 2015 — NBC News
Circumcision Denier Derided
Circumcision reduces the risk of contracting HIV, most scientists agree, but the consensus is not universal. One dissenter is Ronald Goldman, a psychologist in Boston, in the US, who wrote toThe Timesyesterday decrying the use of the procedure as an HIV prophylactic.
July 1, 2015 — The Times (South Africa)
At Last, Gold-Standard Evidence Backs Early Treatment of HIV
The hotly anticipated START trial, designed to answer whether starting HIV treatment at a high CD4 count is preferable to delaying, has been halted more than a year early due to powerful evidence supporting early treatment.
June 1, 2015 — Poz
Early Treatment Best for HIV, Study Confirms
People who started taking AIDS drugs soon after they were diagnosed were healthier and had fewer side-effects than people who waited, a new study found. Researchers were so impressed by the results that they have stopped the study early and will offer the drugs to all the volunteers taking part.
May 27, 2015 — NBC News
Choosing the Worst Time to Scale Back AIDS Research
The search for an effective vaccine is in its most promising phase ever, with some 30 different candidates in the pipeline reflecting an exciting array of scientific approaches. But we don’t yet have all the tools we need, which is why it is the worst time to scale back on AIDS research.
May 18, 2015 — The Hill
Nigeria: HIV Vaccine – Experts Explore Viable Options
As Nigeria joins the rest of the world to mark the HIV Vaccine Awareness Day today, an Associate Professor of Paediatric Dentistry and Consultant at the Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria, Dr. Morenike Ukpong, has called for all hands to be on deck to ensure that all available HIV prevention methods reach people who need them.
May 18, 2015 — All Africa
HIV Vaccines: Our Current Progress (Infographic)
The Bodyshares an AVAC infographic for HIV Vaccine Awareness Day.
May 15, 2015 — The Body
CROI 2015: The Future of Pre-Exposure Prophylaxis (Video)
Mitchell Warren, Jean-Michel Molina, Myron Cohen, Jared Baeton and Simon Collins discuss the future of pre-exposure prophylaxis at CROI 2015.
April 29, 2015 — The Body Pro
Implement HIV Remedies – Expert
African nations should move towards implementation of interventions that have already been proved to work while awaiting a vaccine or cure for HIV and AIDS, a senior HIV and AIDS advocate has said.
March 30, 2015 — The Herald (Zimbabwe)
When HIV Infects the Brain
A new study reports that the virus can infiltrate the central nervous system within months of infection.
March 26, 2015 — The Atlantic
HIV Prevention on the Line: Time to Mobilize — Again
Two meetings decades ago fundamentally changed AIDS treatment for the better. Will Vancouver 2015 be the meeting where science, rights and action get in sync and revolutionize the epidemic once again? Will Durban 2016 lead to massive mobilization for decisive action on ending the epidemic?
March 25, 2015 — Huffington Post
AVAC’s Mitchell Warren on “Intermittent Dosing” & an Integrated Treatment and Prevention Approach for Women
An interview with AVAC Executive Director Mitchell Warren on the new data presented at CROI 2015, what’s next for women and PrEP and why the Partners’s Demonstration project integrated treatment and prevention success is so promising for women.
March 4, 2015 — HIV-e
Studies Support Truvada as Prevention
A range of antiretroviral based prevention trials released data providing strong new evidence for how well daily oral pre-exposure prophylaxis (PrEP) work to prevent new HIV infections. The studies were presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).
February 26, 2015 — Voice of America
HIV Drugs Shown to Be Effective in Trials
Findings from several clinical trials show how well drugs meant to treat the AIDS virus can protect people from becoming infected. But the trials also show that finding prevention methods that people will use is just as important as the medications themselves.
February 24, 2015 — Wall Street Journal
Study That Paid Patients to Take HIV Drugs Fails
Financial incentives do not have a significant effect on HIV drug adherence.
February 24, 2015 — The New York Times
Failure of Anti-HIV Gel Shows Difficulty of Prevention
A vaginal gel containing Gilead Sciences Inc.’s HIV drug Viread, which has shown promise at preventing infections in past tests, was ineffective when used by at-risk women in South Africa, a study found.
February 24, 2015 — Bloomberg Business
Critiquing UNAIDS HIV Prevention Goals, AVAC Calls For Honed Strategy
The global HIV advocacy group AVAC has raised an alarm that global goals for HIV prevention may prove ineffectual due to their vagueness. In a comprehensive report on the state of the HIV epidemic, AVAC has called for more specific targets that harness scientific knowhow in order to deliver reasonable results along a set timeline.
February 23, 2015 — AIDSMeds
With future of HIV prevention “on the line,” AVAC calls for sharper, bolder strategy to end the epidemic
In a report issued today, AVAC warned that global HIV prevention efforts are in jeopardy due to an absence of strategic targets, resources and specific implementation plans to translate science, slogans and goals into action. The report calls for a robust set of global HIV prevention targets tailored to specific interventions and demands action in several key areas of the global AIDS response, including expanded rollout of daily oral pre-exposure prophylaxis, or PrEP, and alignment of science and human rights-based agendas.
February 19, 2015 — PR Newswire
Overcoming HIV Obstacles in 2015
The head of a prominent HIV/AIDS advocacy organization says 2015 will be a year of great opportunities and great challenges.
January 1, 2015 — Voice of America
→ Continue through the archives. Find articles from 2014 and older.